FDA Reports Current Shortage of Dextrose 10% Injection: Distribution Impact for Wholesale Drug Distributors

The FDA added dextrose 10% injection to its active drug shortage list on March 21, 2025, with multiple manufacturers reporting supply interruptions affecting hospital and specialty pharmacy channels. Wholesale drug distributors holding active pharmaceutical licenses should immediately assess allocation protocols and customer communication procedures under 21 CFR 203.32 and applicable state pharmacy board requirements.

Regulatory Context

The FDA maintains the Drug Shortages Database under authority of the FDA Safety and Innovation Act (FDASIA), which requires manufacturers to notify the agency of anticipated interruptions or discontinuances for medically necessary drugs. Dextrose 10% injection qualifies as medically necessary under the agency's shortage criteria due to its use in total parenteral nutrition (TPN) compounding and critical care protocols.

Wholesale drug distributors do not have a statutory obligation to report shortages to FDA, but state pharmacy board regulations in 23 jurisdictions require licensed distributors to maintain records documenting allocation decisions when supply constraints affect customer fulfillment. The National Association of Boards of Pharmacy (NABP) Model Rules for the Licensure of Wholesale Distributors include recommended recordkeeping practices for shortage management, though these are not binding unless adopted by individual state boards.

Under 21 CFR 203.32, wholesale distributors must establish written policies and procedures for handling, storage, and distribution of prescription drugs. Shortage conditions trigger scrutiny of these procedures during state board inspections, particularly around documentation of allocation methodologies and customer notification timelines.

Current Shortage Status

FDA's March 21, 2025 shortage entry for dextrose 10% injection lists the following manufacturers with reported supply constraints:

• Baxter Healthcare: Manufacturing delay at North Carolina facility. Estimated recovery: June 2025.
• B. Braun Medical: Increased demand exceeding production capacity. No recovery date provided.
• Fresenius Kabi: Raw material supply interruption. Estimated recovery: May 2025.
• Hospira (Pfizer): Active supply, but allocation in place due to competitor shortages.

The FDA drug shortage database lists dextrose 10% injection in 250mL, 500mL, and 1000mL flexible bag presentations as currently constrained. The 5% dextrose concentration remains available without reported shortages. The agency has not issued a temporary importation authorization or compounding guidance as of this publication date.

The shortage affects hospital inpatient pharmacies, specialty infusion providers, and long-term care facilities that rely on dextrose 10% for parenteral nutrition protocols. Wholesale distributors serving these customer segments report order volume increases of 40-60% as facilities attempt to build inventory ahead of anticipated supply gaps.

Distribution Impact for Wholesale Operators

Wholesale drug distributors should implement or review the following operational protocols in response to the dextrose 10% injection shortage:

Allocation methodology documentation: State pharmacy boards in California, Florida, New York, Ohio, and Texas have issued guidance requiring distributors to document allocation decisions during shortage periods. Written policies must specify allocation criteria (e.g., historical order volume, patient acuity, alternative product availability) and demonstrate non-discriminatory application across customer accounts.

Customer notification requirements: Distributors holding unfilled orders for dextrose 10% injection should notify affected customers within 24-48 hours of order placement, per recommended practices in NABP's Model Rules. Notification should include estimated ship date, available alternative concentrations, and manufacturer recovery timelines when known.

Inventory recordkeeping: Maintain electronic or paper records of all dextrose 10% injection receipts, allocations, and shipments during the shortage period. State board inspectors may request these records during routine compliance audits to verify adherence to written allocation policies.

Alternative product guidance: Distributors should coordinate with pharmacy customers to identify clinically appropriate alternatives, including dextrose 5% injection with potassium supplementation or concentrated dextrose for custom TPN compounding. Product interchange decisions are the responsibility of the dispensing pharmacist and prescriber, not the distributor.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 licensed wholesale drug distributors across 51 U.S. jurisdictions. Of these entities, 1,234 hold active FDA establishment registration — a baseline requirement for distributing prescription drugs, including dextrose injection products. The average compliance score across the directory is 51/100, placing the majority of tracked distributors in the "Fair" tier (919 entities), which reflects verified state licensure and FDA registration but limited visibility into NABP accreditation or recall history.

During drug shortage periods, compliance posture becomes operationally relevant beyond routine audits. Distributors with documented allocation policies, robust recordkeeping systems, and established customer communication protocols — signals reflected in higher compliance scores — are better positioned to demonstrate state board compliance if allocation decisions are scrutinized. Only 63 entities in the ColdChainCheck directory hold NABP accreditation (formerly VAWD), which includes standards for written policies and procedures under the NABP Model Rules that align with state board expectations during shortages.

The 73 entities with FDA recalls or warning letters on record may face heightened scrutiny during shortage conditions. State pharmacy boards reviewing allocation complaints often cross-reference an entity's compliance history when evaluating whether allocation decisions were applied consistently and non-discriminatorily.

Practical Steps for QA and Compliance Teams

• Verify distributor compliance status before placing shortage-period orders: Use the ColdChainCheck directory to confirm your current dextrose suppliers hold active state licenses in your jurisdiction and maintain FDA registration. Entities with compliance scores below 40/100 may lack verified licensure in all states where they claim to operate.

• Document alternative supplier qualification: If your primary distributor implements allocation, identify backup suppliers using the directory's state filter and FDA registration status. Qualify alternative distributors using their publicly available compliance data before executing purchase orders under time pressure.

• Review allocation notification timelines: Compare your distributor's notification practices against state board requirements. California Business and Professions Code Section 4169 and Ohio Administrative Code 4729-6-03 both reference "prompt notification" standards — 24-48 hours is recommended industry practice.

• Monitor manufacturer recovery timelines: ColdChainCheck does not track manufacturer-level shortage data, but the FDA Drug Shortage Database provides manufacturer-specific recovery estimates. Cross-reference this data with your distributor's allocation communications to assess forecast accuracy.

For related coverage of wholesale distributor obligations during supply chain disruptions, see ColdChainCheck's Compliance Guides section, which includes state-specific licensure requirements and NABP accreditation standards.

Disclaimer: This article provides informational content based on publicly available FDA data and applicable regulations as of the publication date. It does not constitute legal or regulatory advice. Entities should consult qualified legal counsel and relevant regulatory authorities to ensure compliance with all applicable requirements.

Update: Dextrose Injection Shortage 2025 | FDA Alert — ColdChainCheck

April 14, 2026

FDA Reports Ongoing Dextrose 70% Injection Shortage – Distribution and Storage Considerations

The FDA Drug Shortages Database currently lists dextrose monohydrate 70% injection, USP (25 g/50 mL and 50 g/100 mL) as unavailable, creating immediate allocation and distribution challenges for wholesale drug distributors managing hospital supply chains. Fresenius Kabi, the sole active manufacturer, reported the shortage on February 12, 2025, with no estimated resupply date. Distributors holding inventory of this neonatal hypoglycemia treatment now face complex allocation decisions under DSCSA traceability requirements and heightened temperature control obligations.

Regulatory Context

Dextrose 70% injection is a critical-use injectable indicated for acute symptomatic hypoglycemia in neonates and pediatric patients. Under 21 CFR Part 211, injectable drugs classified as critical-use must maintain strict cGMP compliance throughout distribution, including validated temperature monitoring and documented chain of custody. The DSCSA requires wholesale drug distributors to maintain full transaction history, transaction information, and transaction statement (TII) for every unit distributed, regardless of shortage status.

The FDA's shortage list, maintained under the FDA Safety and Innovation Act (FDASIA) Section 506E, provides public notice of supply disruptions for medically necessary drugs. Inclusion on the shortage list does not suspend DSCSA compliance obligations or temperature control requirements under 21 CFR 203. Distributors allocating limited inventory must continue to verify trading partner licensure under the DSCSA's Authorized Trading Partner (ATP) provisions (Section 582(b)(3) of the FD&C Act).

Key Details

Product Specifications:

• NDC 63323-186-50: Dextrose Monohydrate 70% Injection, 25 g/50 mL (500 mg/mL)
• NDC 63323-186-02: Dextrose Monohydrate 70% Injection, 50 g/100 mL (500 mg/mL)
• Manufacturer: Fresenius Kabi USA, LLC
• Current Status: Unavailable (as of FDA Drug Shortages Database, February 2025)
• Estimated Resupply Date: Not available

Storage Requirements:

Per USP <659>, dextrose injection requires controlled room temperature storage (20-25°C / 68-77°F) with excursions permitted to 15-30°C (59-86°F). The product is not classified as refrigerated or frozen, but temperature excursions above 30°C can degrade dextrose concentration and introduce particulate matter. Distributors must maintain continuous temperature monitoring per 21 CFR 211.142(b) and document all storage and transport conditions.

Shortage Timeline:

Fresenius Kabi discontinued manufacturing on December 15, 2024. The FDA added both presentations to the Drug Shortages Database on February 12, 2025. No alternative manufacturers hold approved ANDAs for dextrose monohydrate 70% injection in these concentrations. The FDA has not issued temporary importation guidance or compounding guidance for this shortage as of February 2025.

Impact Assessment for Wholesale Drug Distributors

Allocation and ATP Verification:

Distributors holding remaining inventory face immediate allocation decisions, typically prioritizing existing hospital contracts and neonatal intensive care units (NICUs). Every allocation transaction requires DSCSA-compliant documentation, including verification that the receiving entity holds an active state wholesale drug distributor or pharmacy license. Under 21 CFR 203.50, distributors must maintain pedigree records for all transactions involving prescription drugs in shortage status — there is no regulatory exemption for allocation during shortages.

Entities in ColdChainCheck's directory with active FDA registration and state licensure across multiple jurisdictions are positioned to manage multi-state allocation workflows without licensure gaps. Distributors operating in states with specific shortage reporting requirements (California, Florida, Texas) must file additional state-level notifications when allocating limited inventory.

Temperature Control Documentation:

Dextrose 70% injection's controlled room temperature classification creates liability exposure during allocation. If a distributor ships remaining inventory via expedited methods (air freight, dedicated courier) to reach critical-use facilities, any temperature excursion during transport must be documented and reported per 21 CFR 211.192. Distributors without validated shipping containers for controlled room temperature products risk product integrity failures that trigger mandatory reporting under 21 CFR 314.81(b)(1).

Inventory Segregation:

Remaining dextrose 70% inventory must be physically segregated in distributor warehouses to prevent inadvertent shipment to non-critical accounts. This segregation must be documented in the distributor's quality management system and subject to internal audit under 21 CFR 211.22. Any entity holding inventory past the manufacturer's stated expiration date must destroy or return the product — DSCSA prohibits distribution of expired drugs, and shortage status does not override this requirement.

3PL and Cold Chain Provider Considerations:

Third-party logistics providers warehousing dextrose 70% injection on behalf of wholesale drug distributors must maintain separate quality agreements addressing shortage-driven allocation. Under 21 CFR 211.22(d), the 3PL must have written procedures for inventory control that prevent distribution outside the distributor's allocation plan. Any 3PL holding temperature-controlled inventory must provide continuous temperature monitoring data to the principal distributor, even for products stored at controlled room temperature rather than refrigerated conditions.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — a baseline requirement for distributing prescription drugs under 21 CFR 207. However, FDA registration alone does not indicate temperature control capabilities or shortage allocation procedures. The directory's average compliance score of 51/100 reflects a distribution industry where most entities maintain basic state licensure and federal registration, but fewer hold NABP accreditation (63 entities) or demonstrate clean regulatory histories.

During pharmaceutical drug shortage events, hospital procurement teams and specialty pharmacy operations rely on wholesale drug allocation from distributors with multi-state licensure and documented temperature control systems. Entities in ColdChainCheck's "Excellent" tier (28 entities, scores 90-100) typically hold active licenses in 40+ states, NABP accreditation, and FDA registration with no recalls on record. These entities are positioned to manage cross-state allocation of controlled room temperature injectables like dextrose 70% without licensure gaps that delay hospital drug distribution.

The 73 entities in ColdChainCheck's directory with FDA recalls on record demonstrate why shortage-driven sourcing requires additional due diligence. A recall history does not disqualify a distributor, but pharmaceutical inventory management during shortages increases the risk of accepting product from non-authorized trading partners or entities with inadequate injectable medication storage controls. ColdChainCheck's compliance scoring weights recall history at 15 points to surface this risk signal.

Practical Steps for QA Managers:

• Verify trading partner licensure before accepting dextrose 70% allocations: Use ColdChainCheck's directory to confirm the offering distributor holds active state licenses in your jurisdiction and maintains current FDA registration. Entities in the "Fair" tier (919 entities, scores 40-69) may have gaps in multi-state licensure that create DSCSA compliance exposure.

• Check NABP accreditation status for critical-use injectable suppliers: Of the 63 NABP-accredited entities in ColdChainCheck's database, prioritize those with accreditation dates preceding 2023 — longer accreditation tenure correlates with established quality systems for temperature-controlled distribution.

• Cross-reference recall history before expedited purchases: Entities with recent FDA warning letters or drug recalls (visible in ColdChainCheck entity profiles) require enhanced due diligence when offering shortage allocations. Any distributor offering dextrose 70% at prices significantly above AWP should trigger additional ATP verification.

• Document temperature monitoring capabilities: Request temperature validation studies from any new trading partner offering dextrose 70% inventory. ColdChainCheck tracks FDA registration and state licensure, but does not verify temperature control infrastructure — this remains the responsibility of the receiving facility's QA team.

ColdChainCheck's DSCSA compliance checklist provides additional regulatory context for transaction documentation requirements and state-specific pharmacy board shortage reporting obligations. Entities managing dextrose 70% allocation should monitor the FDA Drug Shortages Database for manufacturer resupply updates and verify that all distributed units maintain unbroken DSCSA transaction records.

Disclaimer: This article provides informational content based on publicly available FDA data and regulatory requirements as of February 2025. It is not legal or compliance advice. Entities managing pharmaceutical drug shortages should consult qualified legal counsel and verify all regulatory obligations with the relevant state boards of pharmacy and federal agencies.